ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.437,66
-0,04%
S&P 500
6.096,35
-0,37%
US Dollar vs BRL
5,9035
-0,38%
Bitcoin
106.473,47
2,41%
Brent Oil
77,675
0,45%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. New River Pharmaceuticals (MM) (NRPH)

  7. New River Pharmaceuticals (MM) (NRPH) Notícias

NRPH

New River (NRPH)

New River Pharmaceuticals (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NRPH
DataHoraFonteTítuloCódigoCompanhia
18/04/200717:41PR Newswire (US)HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite IndicesNASDAQ:NRPHNew River Pharmaceuticals (MM)
03/04/200710:00PR Newswire (US)New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013NASDAQ:NRPHNew River Pharmaceuticals (MM)
19/03/200711:00PR Newswire (US)New River Announces Expiration of Hart-Scott-Rodino Waiting PeriodNASDAQ:NRPHNew River Pharmaceuticals (MM)
13/03/200720:30PR Newswire (US)New River Pharmaceuticals Announces Year-End ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
23/02/200720:07PR Newswire (US)Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamineNASDAQ:NRPHNew River Pharmaceuticals (MM)
20/02/200709:00PR Newswire (US)New River Pharmaceuticals to be Acquired by Shire plc for $64 per ShareNASDAQ:NRPHNew River Pharmaceuticals (MM)
05/02/200713:18PR Newswire (US)New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical ConferenceNASDAQ:NRPHNew River Pharmaceuticals (MM)
25/01/200718:01PR Newswire (US)James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and MarketingNASDAQ:NRPHNew River Pharmaceuticals (MM)
22/12/200602:34PR Newswire (US)New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment ofNASDAQ:NRPHNew River Pharmaceuticals (MM)
07/11/200620:22PR Newswire (US)New River Pharmaceuticals Announces Third Quarter 2006 ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
30/10/200611:00PR Newswire (US)Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific MeetingNASDAQ:NRPHNew River Pharmaceuticals (MM)
13/10/200610:45PR Newswire (US)New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290NASDAQ:NRPHNew River Pharmaceuticals (MM)
06/10/200622:25PR Newswire (US)FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHDNASDAQ:NRPHNew River Pharmaceuticals (MM)
06/10/200622:23PR Newswire (US)New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
03/10/200618:20PR Newswire (US)Dr. Garen Manvelian Joins New River Pharmaceuticals as Chief Medical OfficerNASDAQ:NRPHNew River Pharmaceuticals (MM)
12/09/200616:00PR Newswire (US)New River Pharmaceuticals Inc. Meets Enrollment in NRP104 Adult Phase III StudyNASDAQ:NRPHNew River Pharmaceuticals (MM)
08/09/200618:38PR Newswire (US)New River Pharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare ConferenceNASDAQ:NRPHNew River Pharmaceuticals (MM)
17/08/200619:03PR Newswire (US)New River Pharmaceuticals Names Dr. Samir Roy Vice President, Formulation and ManufacturingNASDAQ:NRPHNew River Pharmaceuticals (MM)
08/08/200618:46PR Newswire (US)New River Pharmaceuticals Announces Second Quarter 2006 ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
25/07/200617:58PR Newswire (US)New River Pharmaceuticals Announces Exercise of Co-Promotion Option in the U.S. for NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
25/07/200613:57PR Newswire (US)New River Pharmaceuticals Closes Sale of $135,000,000 Convertible Subordinated NotesNASDAQ:NRPHNew River Pharmaceuticals (MM)
24/07/200610:41Business WireAMRI Announces Long-Term Manufacturing Agreement with New River PharmaceuticalsNASDAQ:NRPHNew River Pharmaceuticals (MM)
19/07/200622:06PR Newswire (US)New River Pharmaceuticals Prices $125 Million Convertible Subordinated Notes; Company to Repurchase Up to $51 million in CommonNASDAQ:NRPHNew River Pharmaceuticals (MM)
18/07/200618:26PR Newswire (US)New River Pharmaceuticals Announces Proposal to Offer $125 Million Convertible Subordinated Notes; Company to Repurchase up toNASDAQ:NRPHNew River Pharmaceuticals (MM)
30/06/200611:31PR Newswire (US)New River Pharmaceuticals Announces Filing of Investigational New Drug Application for NRP409NASDAQ:NRPHNew River Pharmaceuticals (MM)
23/06/200613:52PR Newswire (US)New River Pharmaceuticals to Host Conference Call on A01, A02 and A03 Clinical Abuse Liability Studies of NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
20/06/200618:30PR Newswire (US)New River Pharmaceuticals Provides Detail on A02 Clinical Abuse Liability Study of NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
18/06/200618:45PR Newswire (US)New River Pharmaceuticals Provides Detail on A01 Clinical Abuse Liability Study and Announces Results from A03 StudyNASDAQ:NRPHNew River Pharmaceuticals (MM)
14/06/200610:01PR Newswire (US)New River Pharmaceuticals to Present Results from NRP104 Abuse Liability StudiesNASDAQ:NRPHNew River Pharmaceuticals (MM)
30/05/200619:33PR Newswire (US)New River Pharmaceuticals to Present at the Friedman Billings Ramsey 2006 Growth Investor ConferenceNASDAQ:NRPHNew River Pharmaceuticals (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:NRPH

Seu Histórico Recente

TSXV
PNV
BIT
NSCIT00128Q8
Kingdom of Spain
BIT
X74772
Natixis Structured Issua...
BIT
S31880
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados